BioMarin Pharmaceutical reported a 32% year-over-year revenue increase to $1.025 billion in Q3 2026, fueled by a 44% rise in metabolic conditions revenue and a 12% increase in skeletal conditions. The company marked its first quarter exceeding $1 billion in revenue, boosted by acquisitions like Amicus Therapeutics and strong demand for treatments such as GALAFOLD and POMBILITI + OPFOLDA. BioMarin also expanded its pipeline with new investigational therapies and anticipates FDA decisions on VOXZOGO in 2027. Despite a GAAP net loss due to acquisition-related costs, non-GAAP income rose, and the company updated its 2026 guidance reflecting order timing uncertainties.
BioMarin Pharmaceutical's stock price on Pluang is currently USD 55.04, down 5.93% as of Nov 03, 2026 04:26 WIB, reflecting market reactions to its latest financial results. The company holds a market cap of $11.33 billion and an enterprise value of $14.66 billion on the platform. This trading activity comes after BioMarin reported its first quarter exceeding $1 billion in revenue, highlighting significant growth in its metabolic and skeletal conditions segments.
